BioSpace News Archive

– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate in the Cantor Fitzgerald “Eyeing Key Events and Programs in the Ophthalmology Space in 2021” virtual panel being held on Fr

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the appointment of Richard Kim to the newly formed role of Chief Commercial Officer. In this role his responsibilities will include leading all aspects of the U.S. commercial launch of the company’s lead program

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 4:20 p.m. ET.

IntelGenx Corp. announced that the United States Patent and Trademark Office has granted a Notice of Allowance for US Patent Application 16/110,737, entitled “Film Dosage Form with Extended Release Mucoadhesive Particles.”.

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company’s fourth quarter and full year 2020 financial results and provide an operational update on Thursday, February 25, 2021, at 7:30 a.m. ET.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has acquired cell sorting technology assets from Propel Labs,

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a fireside chat at the 10 th Annual SVB Leenik Global Healthcare Conference

Investors more than double funding base for cancer microbiome diagnostic company to accelerate go-to-market timeline six months after seed